A West Bengal-based maker of polypropylene woven fabrics and industrial packaging bags opens its Rs 56.12 crore BSE SME issue on September 11
Injecto Polymers Ltd (IPL) operates in the flexible and industrial plastic-packaging segment — the woven sacks, fabrics and bulk bags that move grain, fertiliser, chemicals, minerals and construction materials across India.
It is a B2B manufacturer riding the steady demand for industrial and agricultural packaging, supplemented by a trading arm in plastic raw materials.
The product portfolio is broad and application-diverse. IPL produces polypropylene (PP) woven fabrics (the base material for woven bags), PP woven bags (industrial and agricultural use), Biaxially Oriented Polypropylene (BOPP) bags (for food, consumer goods, medical and hygiene products), leno bags (fruits and vegetables), low-density and polyester pouches (food, pharma, cosmetic, industrial packaging),
Flexible Intermediate Bulk Container (FIBC) bags (chemicals, steel, fertiliser, minerals), and non-woven bags (medical, hygiene, agriculture, reusable shopping). These serve agriculture, construction, textiles, chemicals and consumer goods, customised to shape and size per customer needs.
The model is bulk B2B with a trading overlay. IPL generates a major portion of revenue through bulk orders from institutional and industrial customers, and procures plastic granules (PP, LLDPE, LDPE, HDPE, specialty polymers) and PVC resins in bulk — using part for captive consumption and part for trading, which lets it avail bulk-order discounts.
Quality is validated by ISO 9001:2015 and ISO 22000:2018 certifications plus BIS food-grade packaging certification, supported by an in-house testing facility.
The operating base is in West Bengal. IPL runs two units — Unit I at Jaugram, Jamalpur, and Unit II at Howrah — with in-house testing. As of July 31, 2026, it had 158 employees, and the promoters are the Kolkata-based promoter group behind the company.
Issue Details
| Particulars | Details |
|---|---|
| Issue Opens | September 11, 2026 |
| Issue Closes | September 16, 2026 |
| Listing | BSE SME |
| Listing Date | September 21, 2026 |
| Issue Type | Book Built |
| Price Band | Rs 98 – Rs 100 per share |
| Face Value | Rs 10 |
| Issue Size | Rs 56.12 crore (56,12,400 shares, entirely fresh) |
| Min. Application | 2,400 shares (multiples of 1,200 thereafter) |
| Min. Retail Investment | Rs 2,40,000 |
| Post-IPO Market Cap | Rs 207.90 crore |
| IPO as % of Post-IPO Capital | 27.00% |
| Lead Manager | Indcap Advisors Pvt. Ltd. |
| Market Maker | CapitalSquare Financial Services Pvt. Ltd. |
| Registrar | Integrated Registry Management Services Pvt. Ltd. |
The issue is entirely a fresh issue. From the net proceeds, IPL will utilise Rs 30.50 crore for capex on setting up Phase IV at Unit-I (Jaugram), Rs 10.00 crore for repayment or prepayment of certain borrowings, and the rest for general corporate purposes — a growth-and-deleveraging use of proceeds.
Post-IPO, paid-up equity capital rises from Rs 15.18 crore to Rs 20.79 crore. On capital history, the company issued further equity in the Rs 10.70–100 range between December 2018 and March 2025; promoters’ average cost of acquisition ranges Rs 10.70 to Rs 31.39 per share — against the Rs 100 offer price.
Price Band
At the upper band of Rs 100, on FY26 earnings the issue is valued at a P/E of about 12.99x, with a P/BV of 2.40 on the March 31, 2026 NAV of Rs 41.73, easing to 1.74x on the post-IPO NAV of Rs 57.46. On the cleaner FY25 base the P/E jumps to 25.64x — so on recent average earnings, analysts read the issue as aggressively priced.
GMP Watch
Grey-market interest has been absent.
Financial Performance
| Particulars (Rs cr) | FY24 | FY25 | FY26 |
|---|---|---|---|
| Total Income | 109.80 | 261.85 | 375.83 |
| Net Profit (PAT) | 4.44 | 8.11 | 16.01 |
| PAT Margin (%) | 4.07 | 3.10 | 4.26 |
| RoCE (%) | 10.68 | 13.91 | 15.64 |
The top-line growth has been explosive — total income more than tripled from Rs 109.80 crore in FY24 to Rs 375.83 crore in FY26 (a 138% jump in FY25 alone) — and PAT rose from Rs 4.44 crore to Rs 16.01 crore. On the face of it, impressive.
PAT margins are wafer-thin and volatile, at 4.07% (FY24), 3.10% (FY25) and 4.26% (FY26) — characteristic of the commoditised, low-value woven-packaging business, where a big chunk of “revenue” is pass-through trading of granules.
So this is a high-volume, low-margin business whose rapid revenue growth doesn’t translate into high profitability, and RoCE remains modest at 10–16%. The company reported an average EPS of about Rs 7.87 and an average RoNW of 21.84%.
Peer Comparison
The offer document lists Emmbi Industries and RDB Rasayan as peers, trading at P/Es of roughly 18.7x and 8.03x (as of September 10, 2026).
These differ in scale and product mix, so the comparison isn’t strictly apples-to-apples — and IPL’s ~26x FY25 P/E sits well above RDB Rasayan and above Emmbi, underscoring the aggressively-priced read, even as the FY26 multiple (~13x) looks more moderate.
Risks to Consider
Aggressive valuation is the headline concern. On the cleaner FY25 base the P/E is ~26x, rich for a thin-margin, commoditised woven-packaging SME, leaving little room for operational disappointment.
Thin, volatile margins are structural. PAT margins of 3–4% mean small cost or price movements can swing profitability significantly, and much of the revenue is low-margin trading pass-through — so the impressive top-line growth doesn’t confer pricing power or high returns.
High leverage is a genuine concern. Borrowings of around Rs 101 crore against a net worth of ~Rs 47 crore is high; while Rs 10–12.6 crore of proceeds goes to debt repayment, leverage and finance costs remain a key monitorable.
Raw-material price volatility. The products are polymer-based (PP, LLDPE, HDPE, PVC), so margins are exposed to crude-linked input-price swings; an inability to pass through cost increases would compress already-thin margins.
Receivables and cash-flow quality. Rising trade receivables year-on-year raise a concern over cash conversion.
Woven packaging is crowded and low-barrier, and the Rs 30.50 crore Phase IV capex must translate into utilised capacity and profitable orders to justify the raise. SME-platform liquidity and the large Rs 2.40 lakh minimum retail ticket add to the risk profile.